Asp Isotopes INC Form 4 insider transactions

ASP Isotopes Inc. announced that its subsidiary, Tetra4 Proprietary Limited (a Renergen Limited subsidiary), has entered into a new five-year take-or-pay contract for the sale of liquified natural gas (LNG) from the Virginia Gas Project.

ASP Isotopes Inc. announced its participation in Citi's 2026 Natural Resources Conference, including investor meetings, and provided an update on its proposed merger with ENDRA Life Sciences Inc.

ASP Isotopes Inc. updates shareholders on strong progress in PET Labs and Renergen, with helium production set to commence and significant EBITDA targets projected.

ASPI Isotopes Inc. and ENDRA Life Sciences Inc. have announced plans for a merger, aiming to create a combined entity focused on helium and LNG production.

ASP Isotopes (Noble Africa) details proposed merger with ENDRA Life Sciences, highlighting the critical global helium shortage and the unique Virginia Gas Project.

ASP Isotopes and ENDRA Life Sciences are hosting an investor webinar to discuss the proposed merger of Noble Africa, an ASP Isotopes subsidiary focused on helium and LNG, with ENDRA.

ASP Isotopes Inc. reports that Chief Financial Officer Heather Kiessling sold shares valued at $6.28 per share as part of a pre-arranged trading plan to cover tax obligations.

Donald Ainscow, EVP, Gen Counsel, and Secretary of ASP Isotopes Inc., reported a sale of 100,000 common shares.

ASP Isotopes Inc. Director Todd Wider reported the sale of 100,000 shares of common stock across two transactions on June 29 and June 30, 2026.

Michael Gorley, a Director at ASP Isotopes Inc., reported the sale of 30,000 shares of common stock on June 30, 2026.

ASP Isotopes and ENDRA Life Sciences announce a merger of Noble Africa with a subsidiary of ENDRA, accompanied by a $50 million private placement.

COO Robert Ainscow sold 8,438 shares of ASP Isotopes Inc. to satisfy tax obligations related to restricted stock vesting.

Chairman and CEO Paul Elliot Mann received a substantial stock award and executed planned sales to cover tax obligations.

ASP Isotopes Inc. Chief Operating Officer Robert Ainscow has received a significant equity grant of 800,000 shares, increasing his total stake to over 2.2 million shares.

ASP Isotopes Inc. executive Donald George Ainscow has been granted 400,000 shares of common stock, increasing his total ownership to 900,000 shares.

ASP Isotopes Inc. Chief Financial Officer Heather Kiessling received a significant equity grant of 840,000 shares, vesting over a four-year period.

ASP Isotopes Inc. Chief Operating Officer Robert Ainscow sold 22,500 shares to cover tax liabilities following the vesting of restricted stock.

CFO Heather Kiessling sold 23,124 shares of ASP Isotopes to satisfy tax obligations related to restricted stock vesting.

ASP Isotopes Director Duncan Moore acquired over 62,000 shares through stock awards before selling a portion to cover tax liabilities under a pre-arranged trading plan.

ASP Isotopes Inc. COO Robert Ainscow reported the sale of 25,000 shares of common stock for $4.51 per share, executed under a pre-arranged trading plan.

ASP Isotopes Inc. Executive Chairman Paul Elliot Mann sold 162,153 shares of common stock to cover tax withholding obligations related to a restricted stock award.

ASP Isotopes Inc.'s Chief Financial Officer, Heather Kiessling, sold 80,000 shares of common stock for a weighted average price of $5.798 per share under a Rule 10b5-1 plan.

ASP Isotopes Inc. Director Todd Wider was granted 36,548 shares of common stock as an annual award for his service.

ASP Isotopes Inc. Director Robert John Andrew Ryan acquired 36,548 shares of common stock as an annual restricted stock award, increasing his beneficial ownership to 652,222 shares.

ASP Isotopes Inc. Director Ralph L. Hunter Jr. was awarded 36,548 shares of restricted stock, effective December 18, 2025, as part of his annual compensation.

ASP Isotopes Inc. Director Michael Gorley received an annual award of 36,548 shares of restricted common stock, increasing his beneficial ownership to 117,908 shares.

ASP Isotopes Inc.'s Interim CEO and COO, Robert Ainscow, sold 8,438 shares of common stock at a weighted average price of $6.203 to cover tax withholding obligations.

ASP Isotopes Inc.'s Executive Chairman, Paul Elliot Mann, sold 162,153 shares of common stock on December 1, 2025, to cover tax withholding obligations under a pre-arranged 10b5-1 trading plan.

ASP Isotopes Inc. director Ralph L. Hunter Jr. acquired 10,470 shares of common stock valued at $100,000 as part of his compensation for joining the board.

ASP Isotopes Inc. granted Executive Vice President, General Counsel, and Secretary Donald Ainscow 400,000 shares of common stock effective August 1, 2025, as part of his appointment.